• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在次优治疗期间由于获得补偿性突变导致耐药性HIV-1蛋白酶适应性增加。

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.

作者信息

Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher C A

机构信息

Eijkman-Winkler Institute, Department of Virology, University Hospital Utrecht, The Netherlands.

出版信息

AIDS. 1999 Dec 3;13(17):2349-59. doi: 10.1097/00002030-199912030-00006.

DOI:10.1097/00002030-199912030-00006
PMID:10597776
Abstract

OBJECTIVE

It is thought as a consequence of continuous replication, HIV-1 has acquired an optimal fitness state and that suboptimal antiretroviral therapy selects for drug resistant variants which show impaired fitness in the absence of the drug. In this paper we studied the evolution and fitness of viral populations appearing in a patient who received protease monotherapy.

METHODS

Two factors contributing to fitness, drug resistance and protease catalytic activity, were studied at the enzymatic and virological level.

RESULTS

The first drug resistant viral variants that were selected in vivo harboured one to three protease substitutions. These mutants showed reduced protease activity and consequently a reduction in viral replication capacity. During continued in vivo replication of these viruses in the presence of the drug, novel variants harbouring additional substitutions in the viral protease appeared. These variants did not display any further increase in drug resistance but demonstrated clearly increased protease activity. Consequently the replication capacity of these viruses was raised to a level at which they replicated better than the original wild-type virus.

CONCLUSION

This study indicates that the viral population in the patient does not have to represent the fittest possible variants, and thus antiretroviral therapy may drive the viral population first through a lower fitness level and then to a higher fitness level.

摘要

目的

人们认为,由于持续复制,HIV-1已达到最佳适应状态,而次优抗逆转录病毒疗法会选择出耐药变异体,这些变异体在无药物情况下显示出适应性受损。在本文中,我们研究了接受蛋白酶单一疗法的一名患者体内出现的病毒群体的进化和适应性。

方法

在酶学和病毒学水平上研究了影响适应性的两个因素,即耐药性和蛋白酶催化活性。

结果

在体内选择出的首批耐药病毒变异体含有一至三个蛋白酶替代位点。这些突变体显示蛋白酶活性降低,因而病毒复制能力下降。在药物存在的情况下,这些病毒在体内持续复制期间,出现了在病毒蛋白酶中含有额外替代位点的新变异体。这些变异体的耐药性没有进一步增强,但蛋白酶活性明显提高。因此,这些病毒的复制能力提高到了比原始野生型病毒更好的复制水平。

结论

本研究表明,患者体内的病毒群体不一定代表可能的最适应变异体,因此抗逆转录病毒疗法可能先使病毒群体经历较低的适应水平,然后再达到较高的适应水平。

相似文献

1
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.在次优治疗期间由于获得补偿性突变导致耐药性HIV-1蛋白酶适应性增加。
AIDS. 1999 Dec 3;13(17):2349-59. doi: 10.1097/00002030-199912030-00006.
2
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.1型人类免疫缺陷病毒蛋白酶、逆转录酶、切割位点及p6突变对沙奎那韦、利托那韦与两种核苷类似物四联疗法病毒学应答的影响
AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):487-97. doi: 10.1089/08892220151126526.
3
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.茚地那韦治疗期间的耐药性是由蛋白酶基因及其Gag底物切割位点的突变引起的。
J Virol. 1997 Sep;71(9):6662-70. doi: 10.1128/JVI.71.9.6662-6670.1997.
4
Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.1型人类免疫缺陷病毒中与耐药相关的病毒适应性丧失:蛋白酶抑制剂治疗患者中蛋白酶与gag共同进化的表型分析
J Virol. 1998 Sep;72(9):7632-7. doi: 10.1128/JVI.72.9.7632-7637.1998.
5
Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.在没有蛋白酶抑制剂(PI)治疗的情况下,具有多个PI耐药突变的HIV-1变体的持续存在可以通过补偿性固定来解释。
J Infect Dis. 2007 Feb 1;195(3):399-409. doi: 10.1086/510533. Epub 2006 Dec 29.
6
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.一种基于底物的新型HIV-1蛋白酶抑制剂耐药机制。
PLoS Med. 2007 Jan;4(1):e36. doi: 10.1371/journal.pmed.0040036.
7
Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness.人类免疫缺陷病毒 1 型蛋白酶的进化:对病毒复制能力和蛋白酶稳健性的影响。
J Gen Virol. 2012 Dec;93(Pt 12):2625-2634. doi: 10.1099/vir.0.045492-0. Epub 2012 Aug 29.
8
Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.在基于奈非那韦和洛匹那韦/利托那韦的治疗出现病毒学失败后,HIV-1蛋白酶中的突变模式及相关氨基酸替换
J Med Virol. 2007 Nov;79(11):1617-28. doi: 10.1002/jmv.20986.
9
Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.追溯人类免疫缺陷病毒1型对蛋白酶抑制剂耐药性的进化途径:药物不存在和存在时的病毒适应性。
J Virol. 2000 Sep;74(18):8524-31. doi: 10.1128/jvi.74.18.8524-8531.2000.
10
Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.1型人类免疫缺陷病毒O组逆转录酶和蛋白酶中与体内病毒学治疗失败相关的天然残基与抗逆转录病毒药物选择的突变
AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1385-94. doi: 10.1089/08892220050140937.

引用本文的文献

1
Subtype-Specific HIV-1 Protease and the Role of Hinge and Flap Dynamics in Drug Resistance: A Subtype C Narrative.特定亚型的HIV-1蛋白酶以及铰链区和瓣区动力学在耐药性中的作用:C亚型的阐述
Viruses. 2025 Jul 26;17(8):1044. doi: 10.3390/v17081044.
2
Consensus Sequences for and Introduced into HIV-1 Clade B Laboratory Strains Differentially Influence the Impact of Point Mutations Associated with Immune Escape and with Drug Resistance on Viral Replicative Capacity.引入HIV-1 B亚型实验室毒株的[具体内容]和[具体内容]的共有序列对与免疫逃逸及耐药相关的点突变对病毒复制能力的影响产生不同作用。
Viruses. 2025 Jun 12;17(6):842. doi: 10.3390/v17060842.
3
Noncanonical HIV drug resistance mutations: need to close existing gaps.
非典型HIV耐药性突变:需要填补现有差距。
AIDS. 2025 Jun 1;39(7):781-787. doi: 10.1097/QAD.0000000000004170. Epub 2025 Mar 17.
4
Structural and Functional Studies on HIV Protease: Mechanism of Action, Subtypes, Inhibitors, and Drug Resistance.HIV 蛋白酶的结构与功能研究:作用机制、亚型、抑制剂和耐药性。
Methods Mol Biol. 2025;2867:185-200. doi: 10.1007/978-1-0716-4196-5_11.
5
Modeling Drug Resistance Emergence and Transmission in HIV-1 in the UK.在英国建立 HIV-1 耐药性出现和传播的模型。
Viruses. 2023 May 25;15(6):1244. doi: 10.3390/v15061244.
6
Evolving Mutational Buildup in HIV-1 Protease Shifts Conformational Dynamics to Gain Drug Resistance.HIV-1 蛋白酶中的突变积累导致构象动力学改变从而获得耐药性。
J Chem Inf Model. 2023 Jun 26;63(12):3892-3902. doi: 10.1021/acs.jcim.3c00535. Epub 2023 Jun 7.
7
Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds.抗逆转录病毒治疗 HIV-2 感染:现有药物、耐药途径和有前途的新化合物。
Int J Mol Sci. 2023 Mar 21;24(6):5905. doi: 10.3390/ijms24065905.
8
HIV-1 Protease as DNA Immunogen against Drug Resistance in HIV-1 Infection: DNA Immunization with Drug Resistant HIV-1 Protease Protects Mice from Challenge with Protease-Expressing Cells.HIV-1蛋白酶作为针对HIV-1感染耐药性的DNA免疫原:用耐药性HIV-1蛋白酶进行DNA免疫可保护小鼠免受表达蛋白酶细胞的攻击。
Cancers (Basel). 2022 Dec 30;15(1):238. doi: 10.3390/cancers15010238.
9
Intragenic compensation through the lens of deep mutational scanning.从深度突变扫描视角看基因内补偿
Biophys Rev. 2022 Oct 26;14(5):1161-1182. doi: 10.1007/s12551-022-01005-w. eCollection 2022 Oct.
10
Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins.HIV-1多聚蛋白中变异特异性标志物的遗传多样性及低治疗影响
Front Microbiol. 2022 Jul 14;13:866705. doi: 10.3389/fmicb.2022.866705. eCollection 2022.